In this free webinar, learn about parameters that limit the efficacy of current chimeric antigen receptor (CAR) T-cell therapies and enable the development of CAR T-cells with enhanced performance.

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Researchers at Saint Louis University's School of Medicine say T-cell dysfunction is leading to an increased risk of cancer ...

CART-007, an anti-CD7 CAR T-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic ...

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Ryan Teague, Ph.D., professor of molecular microbiology and immunology at Saint Louis University’s School of Medicine, and his team are now trying to uncover the exact mechanism underlying the ...

and pharmacokinetics as well as anti-tumor activity as assessed by overall response rate, duration of response and disease control rate. ADI-270 is an armored allogeneic “off-the-shelf” gamma delta ...

Tumors find different ways to avoid immune cell detection and proliferate in their environment. Antitumor immune cells will ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...